Sarepta (SRPT) Analysts Split on Accelerated Eteplirsen Approval - Barron's
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Sarepta (SRPT) Trades Higher on Eteplirsen Phase II Update, Analyst Comments
November 12, 2012 11:02 AM ESTSarepta Therapeutics (Nasdaq: SRPT) is trading higher Monday following a presentations by its Chief Medical Officer (CMO) at Action Duchenne, a Duchenne muscular dystrophy (DMD) event held in London this weekend.
According to reports from theStreet.com,... More
Sarepta (SRPT) to Update on Additional Eteplirsen Phase IIb Data
October 12, 2012 4:09 PM EDTSarepta Therapeutics (NASDAQ: SRPT) announced that data from a Phase IIb study evaluating eteplirsen, an investigational treatment for boys with Duchenne muscular dystrophy (DMD), will be presented Saturday, October 13th at the World Muscle Society in Perth, Australia. Principal investigator, Jerry R. Mendell, M.D. of Nationwide Children's Hospital, will present the data in an oral presentation of the abstract titled, "Results at 48 Weeks of a Phase IIb Extension Study of the... More
Sarepta Therapeutics (SRPT) Moves Higher as Ex-FDA Official Sees Accelerated Approval
October 5, 2012 10:24 AM EDTSarepta Therapeutics, Inc. (NASDAQ: SRPT) is moving to the highs of the session and is nearly positive... More
